Patrick DalyPNH | February 6, 2024
The majority of newly diagnosed patients with PNH did not receive a PNH-specific therapy at diagnosis.
Read More
Patrick DalyPNH | January 25, 2024
Levels of lactate dehydrogenase significantly predicted fatigue and QOL in patients with PNH after C5 inhibitor therapy.
Patrick DalyPNH | January 10, 2024
Danicopan added to C5 inhibitor therapy led to significantly improved hemoglobin concentrations in patients with PNH.
Patrick DalyPNH | December 7, 2023
Pozelimab plus cemdisiran achieved intravascular hemolysis control in patients with paroxysmal nocturnal hemoglobinuria.
Patrick DalyPNH | November 27, 2023
The FDA has accepted the BLA for crovalimab, an investigational treatment for paroxysmal nocturnal hemoglobinuria.
Patrick DalyPNH | October 19, 2023
Iptacopan, a complement factor B inhibitor, was effective in patients with PNH with active hemolysis despite eculizumab use.
Rob DillardHematology | October 3, 2023
Take a look at these important studies relevant to anemia, venous thromboembolism, sickle cell disease, and PNH.
Cailin ConnerPNH | September 29, 2023
A study assessed survival and adverse events in patients with PNH treated with eculizumab.
Cailin ConnerPNH | September 15, 2023
Pegcetacoplan is a cost-effective alternative for the treatment of paroxysmal nocturnal hemoglobinuria.
Rob DillardPNH | September 8, 2023
The U.S. FDA has accepted a Biologics License Application for a novel drug to treat paroxysmal nocturnal hemoglobinuria.
Latest News

February 28, 2024